


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	NECEPREVIR SODIUM
PRONUNCIATION	nes e' pre vir
THERAPEUTIC CLAIM	Treatment of Hepatitis C

CHEMICAL NAMES

1. Cyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5*H*)-carboxamide, *N*-(cyclopropylsulfonyl)-6-[2-(3,3-difluoro-1-piperidinyl)-2-oxoethyl]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-2-[[7-methoxy-8-methyl-2-[4-(1-methylethyl)-2-thiazolyl]-4-quinolinyl]oxy]-5,16-dioxo-, sodium salt (1:1), (2*R*,6*R*,12*Z*,13a*S*,14a*R*,16a*S*)-
2. Sodium (cyclopropylsulfonyl){[(2*R*,6*R*,12*Z*,13a*S*,14a*R*,16a*S*)-6-[2-(3,3-difluoropiperidin-1-yl)-2-oxoethyl]-2-({7-methoxy-8-methyl-2-[4-(1-methylethyl)thiazol-2-yl]quinolin-4-yl}oxy)-5,16-dioxo-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-14a(5*H*)-yl]formyl]azanide

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₄₅ H ₅₅ F ₂ N ₆ NaO ₈ S ₂
MOLECULAR WEIGHT	933.1
TRADEMARK	None as yet
SPONSOR	Achillion Pharmaceuticals, Inc.
CODE DESIGNATION	ACH-0142684.Na, ACH-2684.Na
<u>CAS</u> REGISTRY NUMBER	1298053-61-8